Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA (vutrisiran) in ATTR-CM
Nov 9, 2026, 10:54 AM EST2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Five-year positive HELIOS‑B data can support longer-term clinical value and may bolster Amvuttra uptake and revenue potential in ATTR‑CM if corroborated by full data and guideline/label impacts; uncertainty remains on magnitude and payer coverage.
AI summary
What happened, with direct paths to the underlying reporting
Alnylam announced five-year HELIOS-B results showing sustained benefit of AMVUTTRA (vutrisiran) in ATTR-CM.
Alnylam announced five-year HELIOS-B data demonstrating sustained benefit of AMVUTTRA (vutrisiran) in ATTR-CM.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
